We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Center for Drug Evaluation and Research’s Office of New Drugs (OND), part of the U.S. Food and Drug Administration (FDA), is five years into a massive overhaul of the way it reviews and approves new drugs.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor